PAAB: Update on Digitization of Advertising / Promotional Systems (APS)Published on March 18, 2020
Author: Preetha Prabhu
In the light of evolving COVID-19, some manufacturers are modifying how their drug representatives interact with healthcare professionals. PAAB has taken measures to help healthcare product manufacturers comply with regulations during this evolving operational context.
APS that have undergone pre-clearance for use as print materials can be converted to electronic document types (e.g. PDF) without additional PAAB pre-clearance or review provided all of the following conditions are met:
- The entire PAAB approved print document is converted with no change in copy, flow or layout. For example, any size changes are directly proportional throughout the APS.
- No new functionality is added. For example, the document is a flat PDF as opposed to a dynamic PDF with new interactive functionality (e.g. menus, pop-ups, accordions, hover-over tool tips, and so on).
- The print piece is within its PAAB approval period.
Please note that APS digitized in this manner can be distributed to healthcare professionals without informing the PAAB through an FYI notification. These APS should bear the PAAB logo.
Emails used to distribute digitized APS in an unsolicited fashion DO NOT fall under the person-to-person correspondence exemptions in the PAAB code or advertising regulation exemptions in the Health Canada Policy Document “The Distinction Between Advertising and Other Activities”. These emails with attached APS are subject to PAAB review.
To facilitate the review, PAAB recommend submitting an email template. It can include free text portions for transactional elements (e.g. greeting, date and time of phone meeting, sign-off). This enables the template to be multi-purpose and reusable for a variety of products/APSs. It is important that the individuals sending these emails be trained to not include information about the product, disease, or related company services in those free text portions. These individuals should also be trained to not send product branded and unbranded tools in the same email. The submission of the email template should include detailed information regarding the naming convention for email attachments.
PAAB will work with industries to expedite reviews related to digitization efforts.
Clarification regarding digitization of APS: Helping healthcare product manufacturers plan for the evolving COVID-19 operational context (Dated Mar. 13, 2020) https://www.paab.ca/resources/clarification-regarding-digitization-of-aps/
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...
The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022
The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....